Background/Aims: Transforming growth factor-β1 (TGF-β1) plays a crucial role in chronic inflammation in various tissues, and is related to inflammation-caused organ fibrogenesis associated with the epithelial-mesenchymal transition (EMT) and the deposition of the extracellular matrix (ECM). However, the effect of TGF-β1 on bovine mammary epithelial cells (BMECs) with mastitis, and its mechanism, remain unknown. Methods: We analyzed the level of TGF-β1 in inflamed mammary tissues and cells using western blotting. BMECs were treated with TGF-β1, and EMT-related gene and protein expression changes were evaluated using quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunofluorescence. We also inhibited the TGF/Smad signaling pathway using a receptor inhibitor, and analyzed EMT-related protein expression by western blotting. In addition, we injected TGF-β1 into mice mammary glands to investigate whether it can cause mammary fibrosis in vivo. Results: The TGF-β1 level was up-regulated in mammary tissues with mastitis and in inducible inflammatory BMECs. TGF-β1 treatment activated the TGF/ Smad signaling pathway in BMECs during their transition to the EMT phenotype, as indicated by morphological changes from a cobblestone-like shape to a spindle-like one. TGF-β1 treatment also up-regulated the expression of α-smooth muscle actin, vimentin, and collagen I, albumin, and down-regulated the expression of E-cadherin both in mRNA level and protein level. Furthermore, TGF-β1 enhanced the gene expressions of MMP2, MMP7, and fibronectin in BMECs. TGF-β1 injection induced mice mammary infection and fibrosis. Conclusion: These findings suggested that aberrant up-regulation of TGF-β1 in bovine mastitic mammary glands might play an important role in bovine mammary fibrosis caused by unresolved inflammation.
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Introduction
Bovine mammary fibrosis is a common pathological process associated with mastitis, which is the primary clinical disease in cattle [1] . Mastitis has a high incidence and infection rate worldwide, and causes varying extents of bovine mammary fibrosis. The decreased milk production by the fibrotic breast can result in development of mammary sclerosis, which necessitates sacrificing the cow, thus leading to severe economic losses in the dairy industry [2] .. Fibrosis, characterized by the excessive growth of connective tissues and the formation of scleroses and scars, is attributed mainly to the accumulation of the extracellular matrix (ECM) and increase in cytokines, such as transforming growth factor-beta (TGF-β), basic fibroblast growth factor, and platelet-derived growth factor [3] .
A superfamily is a group of multifunctional proteins that play important roles in crucial biological activities. The TGF-β superfamily regulates cell growth and differentiation. At least four subtypes of TGF-β, including TGF-β1, TGF-β2, TGF-β3, and TGF-β1β2, have been found in mammals; however, TGF-β1 is the most studied and is the critical cytokine in the process of fibrosis. Previous research, reviewed by Liu et al [4] ., showed that diseased tissues contain higher levels of TGF-β1, especially in the fibrosis region. Experimental animals treated with exogenous TGF-βl develop tissue and organ fibrosis, as well as excessive deposition of ECM proteins, in their cells. Furthermore, treatments for TGF-βl resistance, including the administration of neutralizing antibodies, a soluble type II receptor, antisense oligonucleotides, small molecule inhibitors, and RNA interference, inhibited the formation of fibrosis [5] .
Recently, research on the role of TGF-β1 in tissue fibrosis has shown that the functional changes resulting from TGF-β1-induced phenotypic changes lead to cell proliferation, ECM deposition, and liver fibrosis [6, 7] . In addition, Liu et al [6] . showed that TGF-β1 induces the conversion of primary kidney fibroblasts into myofibroblasts, increases the expression of α-smooth muscle actin (α-SMA), activates the synthesis of fibronectin, and up-regulates the expression of collagen type I (collagen I) in vitro. Similar effects of TGF-β1 were reported in studies on pulmonary fibrosis [7, 8] .
In addition to producing various ECM proteins, epithelial cells undergo epithelialmesenchymal transition (EMT) in the presence of certain inflammatory cytokines, thereby promoting the occurrence and development of fibrosis [9] . During EMT, epithelial cells acquire certain characteristics of the stromal cells around them, as seen by the loss of epithelial polarity and the acquisition of stromal features, including a stromal-like appearance, and vimentin, snail, and osteopontin expression [10, 11] . Epithelial cells often change from a cobblestone-shape to a spindle-shape, the level of E-cadherin decreases, and those of vimentin, α-SMA, and fibronectin increase; after EMT, epithelial cells show functional similarity to fibroblasts.
Recent research has focused on the theory that EMT can increase cancer cell invasion and metastasis [12, 13] ; however, little work has been carried out on tissue fibrosis caused by EMT. Kaimori et al. confirmed that exogenous TGF-β1 induced EMT in mouse liver cells via the Smad2/3 pathway, demonstrated mainly by the morphological change from a hexagonal cell shape to a spindle-shape [7, 14] . Vimentin and albumin expression levels also decreased significantly at the gene and protein levels [7] . In addition, Chen et al [9] . demonstrated that TGF-β1 induces EMT in human lung cancer A549 cells, as demonstrated by changes in mesenchymal morphology, increase in invasion and metastasis ability, up-regulation of the mesenchymal marker genes encoding vimentin and fibronectin, and down-regulation of the epithelial marker E-cadherin [15, 16] .
A deeper understanding of the role of TGF-β1 in bovine mammary fibrosis and mastitis could lead to the development of new therapeutic methods to prevent fibrosis during the early phase of bovine mammary mastitis, and could assist in curing mammary fibrosis. Hence, we studied the effects of TGF-β1 in mammary mastitis and fibrosis by stimulating bovine mammary epithelial cells (BMECs) with exogenous TGF-β1. Morphological and functional changes were studied, in addition to investigating the possible signaling pathways involved.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry Table 1 . PCR primers used in the present study Table 1 . PCR primers used in the present study Gene name Forward Primers(5'-3') Reverse Primers (5'-3')  GAPDH  GGCGTGAACCACGAGAAGTA  GGCGTGGACAGTGGTCATAA  α-SMA  GAAGCCCAGCCGAGAACTTT  TCCCACCATCACTCCCTGAT  E-cadherin  AAAGAGAGTGGAAGTGCCCG  GCAGGTGGAGAACCATTGTC  vimentin  GTCCAAGTTTGCTGACCTCTC  TAGTCCCTTTGAGCGCATCC  fibronectin  AACCCTTCCACACCCCAATC  CCGGGAAGCTGAATACCGTT  collagen I  ACTGAAACCCCCGAAAAGCC  GTGGGTCTTCAAGCAAGTGG  albumin  CCAAGGCAACAGAGGAACAAC  TCAGGTAGGCTGAGATGCCTT  MMP2  ACCAAGAACTTCCGCCTGTC  TTCGCCAGATGAATCGGTCC  MMP9  CAGACCTTTGAGGGCGAACT  TACCCATCTCCGTGCTCTCT  Smad2  TGGAGGAGAGCAGAATGGAC  CTGTAAAGGCCTGTTGTATCCC  Smad3  GCCGAGAGTTGAAGCGAAGT  CTCTTGACTGCCTTCTCGCA  Smad4 CCCCAGCCATCAGTTTGTCG GTCGGCAATAGGCATGGTGT
Materials and Methods
Cell culture and treatment Primary BMECs were derived from healthy lactating bovine by our research group during previous research [17] . BMECs were recovered and cultured in DMEM/F12 with 10 % fetal bovine serum, 100 IU/mL of penicillin, and 100 µg/mL streptomycin (GibcoBRL, Grand Island, NY, USA).
BMECs were seeded in 60-mm culture dishes. Six hours after seeding, the culture medium was replaced with or without TGF-β1 (2 ng/mL, Creative BioMart, Shirley, NY, USA), according to manufacturer's instructions. Cells were cultured for 72 h and photographed every 12 h under a phase-contrast microscope, before being harvested for subsequent experiments.
To inhibit the TGF/Smad pathway, the cells were treated with LY2109761 (Selleck Chemicals, Houston, TX, USA), a TGF-β receptor type I/II inhibitor, at a final concentration of 10 µmol/mL for six hours. This was followed by treatment with TGF-β1 at the aforementioned concentration. After incubation with both LY2109761 and TGF-β1 for 72 h, the cells were harvested for subsequent experiments.
Enzyme-linked immunosorbent assay (ELISA)
TGF-β1 secreted into the culture supernatants by BMECs was measured by ELISA. BMECs were stimulated with lipoteichoic acid (LTA) (20 ng/µL) for 12 h or lipopolysaccharide (LPS) (10 ng/µL) for 3 h, based on an inflammatory cell model of bovine mastitis established in a previous publication [18] . The medium was replaced with fresh serum-free medium, harvested 24 h later, and centrifuged to remove cell debris. Culture supernatants were used to measure TGF-β1 levels using a bovine TGF-β1 analysis ELISA kit (Huzhen Biological Technology, Shanghai, China), according to manufacturer's instructions.
Total RNA extraction and quantitative real-time polymerase chain reaction (qPCR)
Cells were washed and re-suspended in ice-cold TriZol solution (TransGene, Shanghai, China). Total mRNA extraction was performed using an RNA Easy Kit (TransGene), according to the manufacturer's instructions. The concentration of mRNA was measured using a spectrophotometer (ND 2.0; NanoDrop Technologies, Wilmington, DE, USA). One microgram of total RNA from each sample was reverse-transcribed into cDNA using a TransScript II First-Strand cDNA Synthesis SuperMix (TransGene).
Real-time PCR was performed with an ABI StepOnePlus PCR system (Applied Biosystems, Foster City, CA, USA), using the TransStart Probe qPCR SuperMix (TransGene) and the reaction system recommended by the manufacturer. Specific forward and reverse PCR primers were purchased from Sangong Biotech (Sangong Biotech, Shanghai, China), and are listed in Table 1 .GAPDH was used as an internal control in all reactions. The PCR conditions were as follows: activation at 95 °C for 30 s, followed by 40 cycles of denaturation at 95 °C for 5 s, extension at 60 °C for 30 s. Melt curves were generated to evaluate the specificities of the primers. The comparative cycle threshold (Ct) method was used to quantify normalized target gene expression relative to the calibrator. Data are shown as the relative gene quantity (RQ) =2 -ΔΔCt .
Western blotting analysis
Mammary tissue was obtained from dairy cows, with or without mastitis, and confirmed by macroscopic dissection, followed by microscopic examination, in our previous work [17] . The tissues were ground into powder in liquid nitrogen, and cells or tissue powders were lysed in PRO-PREP Protein Extraction Solution (iNtRON Biotechnology Inc., Gyeonggi-do, Korea). The precipitate was removed by centrifugation, and the supernatant was mixed with 6 × SDS sample buffer (TransGene) and boiled at 100 °C for 5 min. The mass of total protein was determined using the Bradford Easy Protein Quantitative Kit (TransGene). Total protein, ranging from 20 μg to 40 μg for each sample, was resolved by SDS-PAGE on a 10% Bis-Tris Gel with running buffer, and transferred to Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry polyvinylidene difluoride membranes. The membranes were blocked with 10% non-fat milk in Tris Buffered Saline Tween (TBST) at 23-28 °C for 2 h. The blots were then probed with antibodies against TGF-β1, Smad2 (Phospho-Ser467) and Smad2 (1:500 dilution, Sangong Biotech); α-SMA (1:1000 dilution, Sigma-Aldrich, St Louis, MO, USA); vimentin and collagen type I (1:500 dilution, Beijing Biosynthesis Biotechnology, Beijing, China); albumin (1:1000 dilution, Bethyl Laboratories, Montgomery, TX, USA); E-cadherin (1:500 dilution, Sigma-Aldrich); and GAPDH (1:500 dilution, Santa Cruz Biotechnology, Dallas, TX, USA). Primary antibodies were diluted with 5% non-fat milk and incubated with the membranes at 4 °C overnight. After washing with TBST, the membranes were incubated with corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies. Finally, an enhanced chemiluminescence detection kit (Beyotime, Beijing, China) was used to visualize the immunoreactive proteins.
Immunofluorescence (IF) Staining
BMECs were seeded in 48-well culture dishes and treated with TGF-β1 as mentioned above. The culture medium was discarded after the treatment and the cells were washed three times with normal saline (NS). Cells were fixed with 4% paraformaldehyde in NS for 15 min and permeabilized in 0.5 % Triton X-100/ PBS for 5 min at 23-28 °C. After washing with NS, cells were blocked with immunofluorescence sealing fluid (Beyotime) for 1 h at 23-28 °C and incubated with specific primary antibodies at 4 °C overnight. The primary antibodies included anti-α-SMA (1:500; Sigma-Aldrich), anti-vimentin, anti-collagen I (1:200; Beijing Biosynthesis), and rabbit anti-Smad4 (1:200; Sangon Biotech). Finally, the cells were washed with NS and incubated with corresponding fluorescein isothiocyanate (FITC)-conjugated secondary antibodies for 2 h at room temperature. Note, for F-actin staining, the cells were only incubated in FITC Phalloidin (Yeasen, Shanghai, China) for 15 min. Hoechst 33342 (Sigma-Aldrich) was used to visualize the nuclei. IF was viewed under an immunofluorescence microscope.
Intramammary challenge with TGF-β1 in mice
Two to three-month-old female Kunming strain mice were obtained from the Laboratory Animal Center of the Fourth Military Medical University (Xi'an, Shaanxi, China) and fed carefully according to the institutional guidelines of Northwest A&F University. Animal experiments conformed to the regulations approved by the Animal Care Commission of the college of Veterinary Medicine, Northwest A&F University.
On days 7 to 10 of lactation, 12 mice were separated into two groups randomly, narcotized with pentobarbital sodium, and fastened supinely. The abdomen areas of all mice were disinfected with alcohol wipes, and the top 2-3 mm of the nipples at the 4th pair of mammary glands were removed quickly with ophthalmic scissors. Then, 50 µL of TGF-β1 (10 ng/mL), diluted in NS, was injected into the 4th left mammary gland through the milk ducts using a 1000-μL syringe with a 30-gauge blunt needle; the 4th right mammary gland was injected with 50 µL of NS as a control. After injection, mice were placed supinely in separate clean and warm cages. One group of mice were given a single injection, and the other group of mice given a multiple injections in quadruplicate with a 3-day interval. Three days after the last injection, the mice were killed by cervical dislocation, and the 4th pair of mammary glands were extracted and fixed in 4% formaldehyde overnight. Four slices of each sample were prepared for routine histopathological analysis using hematoxylin and eosin staining.
Statistical analysis
A two-tailed test was used in this study, and the data are presented as mean ± SD. Differences were considered significant if the p value was less than 0.05 (*P < 0.05; **P < 0.01). All data are representative of at least three different experiments and were analyzed using GraphPad Prism software (San Diego, CA, USA).
Results
TGF-β1 expression in bovine mammary tissue with or without mastitis and inducible inflammatory BMECs.
Analysis of TGF-β1 levels in mammary tissue from four healthy and four mastitic dairy cow mammary glands indicated that TGF-β1 levels were higher in mastitic tissue than in normal tissue (Fig. 1a) .
Cellular
To confirm the correlation between TGF-β1 and inflammation, BMECs were treated with LTA or LPS, and TGF-β1 levels were evaluated. The western blotting results showed that TGF-β1 levels in LTA-BMECs and LPS-BMECs were higher than those in normal BMECs (Fig. 1b) . Secretion of TGF-β1 in LTA-BMECs and LPS-BMECs was also measured using ELISA and the results were consistent with those obtained by western blotting (Fig. 1c) .
TGF-β1 induced mesenchymal phenotype changes in BMECs
To determine the function of TGF-β1, normal BMECs were treated with TGF-β1 (2 ng/ mL) for 72 h and photographed every 12 h under a phase-contrast microscope. The images of the control and treated samples at 36 h and 72 h are shown as typical examples. Cells began to change shape at an early stage (24 h), and by 36 h had changed from a hexagon to a spindle-shape, which is recognized as a mesenchymal phenotype. The morphological changes became increasingly obvious throughout the treatment (Fig. 2a) . The presence of The results showed that TGF-β1-treated BMECs acquired a mesenchymal morphology (Fig. 2b) , which correlated with the cell shape observed under the phase-contrast microscope.
TGF-β1 promoted the expression of α-SMA in BMECs
In addition to morphological changes, the up-regulation of α-SMA, a well-known marker of EMT, was confirmed at the gene and protein levels (Fig. 2c-d ). BMECs were treated with TGF-β1 (2 ng/mL) for 72 h, and harvested at 36 h and 72 h. Samples analyzed by qPCR and western blotting to determine if TGF-β1 induced α-SMA expression. The mRNA levels of α-SMA reached a peak at 72 h. As a result, we treated BMECs with TGF-β1 at a concentration of 2 ng/mL for 72 h as the uniform treatment method for subsequent experiments.
TGF-β1 induced an EMT state in BMECs
The significant morphological changes and up-regulation of α-SMA levels suggested that TGF-β1 induces EMT in BMECs. To confirm this, the expression levels of several genes encoding widely recognized EMT markers, including E-cadherin, vimentin, fibronectin, collagen I, albumin, matrix metalloproteinase-2 (MMP2), and matrix metalloproteinase-9 (MMP9), were examined. The results of the qPCR analysis showed that TGF-β1 downregulated the expression of E-cadherin, whereas it up-regulated the mRNA expression of all the other EMT-related genes (Fig. 3a) . This is supported by western blot analysis of albumin, collagen I, E-cadherin, and vimentin protein levels (Fig. 3b) . The results were further confirmed by IF staining showing elevated levels of α-SMA, vimentin, and collagen I following TGF-β1 treatment (Fig. 3c) .
TGF-β1 upregulated the expressions of Smad2 and Smad3 in BMECs
To understand how TGF-β1 causes EMT in BMECs, activation of the TGF/Smad signaling pathway, which is closely related to EMT, was examined. Gene expressions of Smad2, Smad3, and Smad4, which are key molecules in the TGF/Smad pathway, were evaluated using qPCR. 
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Smad2 and Smad3 expressions were up-regulated after TGF-β1 stimulation; however, the expression of Smad4 did not change (Fig. 4a) . Phosphorylation of Smad2 is a universally recognized marker of the activated TGF/ Smad signaling pathway [19] . Using western blotting, we showed that level of p-Smad2 was elevated significantly after TGF-β1 treatment (Fig. 4b) .
Smad4 is translocated into the nucleus of BMECs after treatment with TGF-β1
Previous research showed that Smad4 is transported into the nucleus when the TGF/ Smad signaling pathway is activated [20] . In the present study, IF staining of Smad4 showed that in normal BMECs, Smad4 was distributed in both the cytoplasm and the nucleus. When The protein expression of p-Smad2 and α-SMA in BMECs was measured using western blotting. LY2109761 was added at the following concentrations: 1 µm/mL, 5 µm/mL, and 10 µm/ mL. (b) The amounts of p-Smad2, Smad2, albumin, collagen I, E-cadherin, and vimentin in BMECs were measured using western blotting. Smad2 was used as an internal control for p-Smad2. Control, normal BMECs; TGF-β1, BMECs treated with TGF-β1; LY2109761+ TGF-β1, BMECs treated with LY2109761 and TGF-β1. 
treated with TGF-β1, however, Smad4 was enriched in the nucleus and was barely detectable in the cytoplasm, which indicated that Smad4 is translocated into the nucleus after TGF-β1 stimulation (Fig. 4c) .
LY2109761 suppressed SMAD2 phosphorylation and α-SMA expression
To further confirm that TGF-β1 causes EMT in BMECs via TGF/Smad signaling, TGF receptors I and II were inhibited using LY2109761, which was added under a concentration gradient. The appropriate experimental concentration was chosen based on the downregulation of p-Smad2 and α-SMA. Western blotting analysis indicated that p-smad2 and α-SMA levels were down-regulated strongly by 10 µmol/mL LY2109761 (Fig. 5a) , which indicated the successful inhibition of the TGF/Smad signaling pathway. Thus, 10 µmol/mL was chosen as the final concentration for use in subsequent experiments.
LY2109761 suppressed TGF-β1-induced protein level changes
LY2109761 was added into the culture medium 6 h before TGF-β1 treatment. Upregulated p-Smad2, albumin, collagen I, and vimentin levels were observed in the TGF-β1 treated group, but disappeared in the LY2109761+TGF-β1 treatment group (Fig. 5b) . Conversely, the E-cadherin level increased in the LY2109761+TGF-β1 treatment group compared with the TGF-β1 treatment group. The results indicated that TGF-β1's effects on BMECs are inhibited by LY2109761.
TGF-β1 caused obvious inflammation and fibrosis in a mouse model
In the present study, we demonstrated the fibrosis-inducing function of TGF-β1 in BMECs; however, to ascertain whether TGF-β1 also induces fibrosis in vivo, a mouse model was used. No fibrosis or inflammation was observed in the control group or the TGF-β1 treated group with a single injection. Alveoli with large luminal areas were integrated; no infiltration of leukocytes in the alveoli or hyperplasia in the connective tissue around the alveoli were observed in the tissue sections ( Fig. 6a and b) . However, significant fibrosis and inflammatory infiltration were evident in the mammary glands in those mice that received multiple injections, as indicated by damaged alveoli, stratified epithelium, and the large number of collagen fibers around the alveoli. In addition, some alveoli were filled with exfoliative epithelium (Fig. 6c) .
Discussion
This study was the first to confirm that TGF-β1 can induce EMT and the accumulation of ECM proteins in BMECs. We demonstrated that aberrant up-regulation of TGF-β1 in the mammary glands of bovine with mastitis could cause a mesenchymal morphology and functional changes in BMECs via the activation of the TGF/Smad signaling pathway, thereby contributing to the fibrogenesis of bovine mammary glands. Exogenous TGF-β1 also induced mammary fibrosis in mice. Thus, our findings provide a theoretical basis for the prevention of bovine mammary fibrosis induced by mastitis.
TGF-β1 is a multifunctional cytokine that modulates diverse cellular activities, such as regulating the growth, differentiation, and function of immune and non-immune cells. Upregulated expression of TGF-β1 has been described in the rat small intestine and mouse mammary glands, mainly in infected cells showing an inflammatory response [21] . This study represents the first demonstration that the level of TGF-β1 is increased in mammary tissue with mastitis and in LPS or LTA-induced inflammatory BMECs. Accumulating evidence suggests that TGF-β1 promotes fibrosis in many kinds of tissues [6, 7, 22, 23] , and the critical role played by TGF-β1 in the initiation, development, and persistence of radiation fibrosis has been reviewed [21] . Inflammation is recognized as the earliest stage of fibrosis, and long-term inflammation is associated with the development of fibrogenesis [24, 25] . In other words, inflammation is essential for the onset of fibrosis [26] . Mastitis has a high incidence and infection rate worldwide, and causes varying extents of bovine mammary fibrosis. Thus, identifying the role of elevated TGF-β1 in mammary glands in the process of mastitis and clarifying its mechanism of action might lead to the development of new methods to resist the fibrosis-inducible function of TGF-β1 in bovine mastitis.
With this goal in mind, we developed an in vitro model by treating cultured BMECs with TGF-β1 to investigate whether TGF-β1 mediates the bovine mammary fibrosis caused by mastitis. EMT is associated with fibrosis in the kidney, liver, and intestines [27] [28] [29] . Upregulation of α-SMA and vimentin and down-regulation of E-cadherin are reliable markers that characterize EMT during the development of fibrosis in a variety of organs [30] [31] [32] . As expected, our findings revealed that TGF-β1 induces EMT in BMECs, with marked molecular changes.
ECM proteins, such as fibronectin and collagen I, constitute complex grid structures that support and connect surrounding connective tissues [33] . The overexpression of ECM proteins, combined with the obstruction of their degradation, contributes to the accumulation of the ECM, eventually leading to tissue fibrosis [34] [35] [36] [37] [38] . Moreover, Kim et al. found that the ECM can regulate EMT during pulmonary fibrosis [39] . Using western blotting analysis, we proved that TGF-β1 caused an increase in the level of collagen I, a major ECM protein (Fig. 3b) . In addition, histopathological analysis of mouse mammary glands revealed dense bundles of collagen fibers in the glands. Consequently, accumulation of the ECM stimulated the expression of MMP2 and MMP9. We also observed an increase in albumin levels after TGF-β1 treatment, which contradicts a previous report [7] .
When the TGF/Smad signaling pathway is activated, Smad2 is phosphorylated by a type I receptor kinase, and Smad4 is translocated into the nucleus [19, 40] . Furthermore, Smad3 is present at high levels in fibrotic tissues [41] , and up-regulated Smad2 expression compensates for Smad3 [42] [43] . We found that the mRNA expressions of Smad2 and Smad3 were elevated and the amount of phosphorylated Smad2 was up-regulated conspicuously. In addition, Smad4 was translocated to the nucleus, as shown in the IF staining result.
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LY2109761 blocked the effects of TGF-β1 treatment, which indicated that TGF-β1 induces EMT and ECM-related protein accumulation via the TGF/Smad signaling pathway. Based on these results, we assessed whether TGF-β1 induces mammary fibrosis in vivo. Pathological analysis showed apparent fibrosis and inflammation in mammary glands that were injected with TGF-β1 four times, but not in those treated once, suggesting that longterm TGF-β1 treatment can induce mammary infection and fibrosis in mice, which also supported the correlation between mastitis and mammary fibrosis.
Conclusion
The high level of TGF-β1 in mastitic tissues and LTA/LPS-induced inflammatory BMECs suggested that TGF-β1 is an important factor in the transition phase from mammary inflammation to fibrosis. Characteristic changes in the morphology and function of TGF-β1-treated BMECs suggested that TGF-β1 plays a significant role in EMT and in ECM protein accumulation. The inflammation and fibrosis of mouse mammary glands induced by TGF-β1 further indicated the crucial role of TGF-β1 in bovine mammary fibrosis. However, further study of the function of TGF-β1 in bovine mammary fibrosis is needed to develop new therapies to stop deterioration of mammary fibrosis at the early stage.
